tbuckley/cabot-search huggingface dataset:
Comparative Prices of Various Proprietaries and Pharmacopeial Preparations.
Authors: Edward P. Stimson
Journal: JAMA (1906)

Tiverton, Mass., Nov. 12, 1906. <h3>To the Editor:</h3> —I have just received samples of cystogen from St. Louis. The price is $1 an ounce. Why should not the physician keep himself posted in the current prices of preparations and not be imposed on by these firms who are filling the shelves of the druggist and the table of the physician with goods under some fanciful name when the same thing can be obtained from some reputable manufacturer at about one-sixth of the price. For example, Mallinckrodt lists hexamethylenamin at 17 cents an ounce, $1.75 a pound, while Merck lists the same preparation, under the trade name of formin, at the same price. In the article advertised by the Cystogen Chemical Company there does not appear to be any deception except in the name and the statement that it is "A preferred product of hexamethylene tetramine remarkably free from irritating properties."
Management of faecal incontinence in adults: summary of NICE guidance
Authors: Christine Norton, Louise Thomas, Jennifer Hill
Journal: BMJ (2007)

Why read this summary?The prevalence of faecal incontinence in adults living in the community is 1-10%, depending on the definition used. 1 2 Faecal incontinence is a neglected problem that receives limited medical attention, and despite its profound negative impact most patients do not tell their doctor about it. 3 4Simple, low cost interventions will often improve or even cure symptoms.More sophisticated second line investigations and treatments are available, but referral for these is not common.This article summarises the most recent guidance from the National Institute for Health and Clinical Excellence (NICE) on managing faecal incontinence in adults. 5Recommendations NICE recommendations are based on systematic reviews of best available evidence.When minimal evidence is available, a range of consensus techniques is used to develop recommendations.In this summary, recommendations derived primarily from consensus techniques are indicated with an asterisk (*).
Spontaneous Functional Closure of Symptomatic Atrial Septal Defects
Authors: Glen G. Cayler
Journal: New England Journal of Medicine (1967)

SPONTANEOUS closure of ventricular septal defects, which was first postulated on the basis of changing clinical findings in 19181 2 3 and first demonstrated by serial cardiac-catheterization studies in 1957,4 has now been documented as occurring during infancy,5 6 7 childhood,7 8 9 and adulthood.10 11 12 13 14 Medical management of ventricular septal defects during infancy is usually recommended since even large defects associated with large left-to-right shunts and congestive heart failure have been observed to undergo spontaneous functional closure.4 5 6 7 , 15 Delayed spontaneous closure of patent ductus arteriosus has also been reported in premature babies,16 , 17 children18 19 20 21 22 23 and adults.20 , 24 In premature babies with large ductal shunts and congestive heart failure it . . .
lndium-111 Chloride Imaging with Ununited Fractures
Authors: BETTYE A. SAYLE, H DANIEL FAWCETT, WILLIAM M. YUDT, STEPHEN C-Y. WANG, JON T. MADER, GEORGE CIERNY
Journal: Clinical Nuclear Medicine (1987)

Twenty patients with ununited fractures and a suspicion of infection had ln-111 chloride imaging. Surgically obtained cultures were positive for infection in 12 and negative in eight patients, ln-111 chloride images were positive in all 12 patients with infection but also were positive in six of the patients with negative cultures. It is not possible to differentiate infected from noninfected ununited fractures by ln-111 chloride imaging.
A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway
Authors: Xinliang Mao, Biyin Cao, Tabitha E. Wood, Rose Hurren, Jiefei Tong, Xiaoming Wang, Wenjie Wang, Jie Li, Yueping Jin, Wenxian Sun, Paul A. Spagnuolo, Neil MacLean, Michael F. Moran, Alessandro Datti, Jeffery Wrana, Robert A. Batey, Aaron D. Schimmer
Journal: Blood (2010)
RE: Courage Beyond Science
Authors: Paul deR Kolisch
Journal: JAMA (1977)

<h3>To the Editor.—</h3> "Courage Beyond Science" (236:2085, 1976) is a delightful, discursive piece that is a welcome relief from the usual fare in our journals. It is, unfortunately, so well constructed that glaring errors of fact may be readily swallowed by the unwary. Before asserting that E. Grey Dimond should have known better, I looked him up in the<i>Directory of Medical Specialists</i>. Since he is my junior in medicine by two years, I am on solid ground. As far as "none of the following medical aids..." and as far as "remarkable technical events unknown..." are concerned, I assert that I knew about some of them and that I should have known about still more before I reached for my diploma in the old Brooklyn Academy of Music, in May of 1942. Antibiotics may be an imprecise term, but we knew about them and, as a matter of fact, administered
The Development of Medicine as a Profession: The Contributions of the Medieval University to Modern Medicine
Authors: Lester S. King
Journal: JAMA (1967)

Bullough has set himself the problem: How did medicine get to be a profession? Medicine, he believes, was one of the first groups to gain "professional recognition," and this process he tries to "examine historically." What, then, is a profession? "In simple terms a profession is a high status group which has become institutionalized." Bullough tries to indicate the several steps whereby this institutionalization took place and the way medical men tried to achieve status. This latter step, it seems, involved formal organization, conflict with competing groups, and attempts to curry favor with authorities and to improve the public image. In a brief 110 pages he races through medical history from ancient Egypt to the 15th centuryAD, picking out whatever information bears on this concept of "professionalization." Instead of bringing out the relation of medicine to the thought and culture of the times, Bullough presents isolated details and quotations,
Abstract 829: Down-regulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer
Authors: Jun Okamura, Yiping Huang, Mariana Brait, Xiaofei Chang, David Sidransky, Myoung S. Kim
Journal: Cancer Research (2012)

Abstract Cisplatin is an effective anticancer drug used to treat many types of cancer, including non-small cell lung carcinoma (NSCLCs), but development of resistance is the primary impediment in cancer treatment. Insulin-like growth factor-binding protein 7 (IGFBP7) is a secreted tumor suppressor that is inactivated in human lung cancer. IGFBP7 is known to alter sensitivity to interferon-based anticancer therapy, and here, we examined loss of IGFBP7 as a potential contributor to chemo-resistance to cisplatin. The transcriptional level of IGFBP7 was decreased in cisplatin-resistant human cancer cell lines and NSCLC xenografts. IGFBP7 knock-down increased cellular resistance to cisplatin and increased the level of mitogen-activated protein kinase phosphatases (MKP) 3 levels. The expression of MKP3 increased in a cisplatin-resistant NSCLC cell line and lung xenografts. MKP3 knock-down increased IGFBP7 level, indicating that MKP3 regulates IGFBP7. These findings suggest a novel molecular mechanism responsible for the tumor suppressive function of IGFBP7 in cisplatin-resistant human lung cancer and could lead to the development of IGFBP7 as a cisplatin-sensitizing agent. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 829. doi:1538-7445.AM2012-829
Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure
Authors: Robert J. Mentz, Susanna R. Stevens, Adam D. DeVore, Anuradha Lala, Justin M. Vader, Omar F. AbouEzzeddine, Prateeti Khazanie, Margaret M. Redfield, Lynne W. Stevenson, Christopher M. O’Connor, Steven R. Goldsmith, Bradley A. Bart, Kevin J. Anstrom, Adrian F. Hernandez, Eugene Braunwald, G. Michael Felker
Journal: JACC Heart Failure (2014)
Argentina suspends non-emergency health benefits for pensioners
Authors: S. Arie
Journal: BMJ (2001)

Millions of elderly Argentinians who rely on social security for everything from lifesaving cancer treatment to hearing aids have been cut off overnight by a system that has run out of money after three years of crippling recession and decades of corrupt management.

“They've stopped sending a nurse to my home, and I haven't had my allowance for six weeks now,” said 62 year old Augustina Lanus from Buenos Aires. “They said they just haven't got the money. But I'm so worried. I need my medication. I don't know what I'm supposed to do.”

Argentina's health insurance system for pensioners (the Integral Programme for Medical Assistance) suspended all non-emergency benefits …
Thiazide Diuretics and the Risk for Hip Fracture
Authors: Mariette W.C.J. Schoofs, Marjolein van der Klift, Albert Hofman, Chris E.D.H. de Laet, Ron M.C. Herings, Theo Stijnen, Huibert A.P. Pols, Bruno H.Ch. Stricker
Journal: Annals of Internal Medicine (2003)

Since most hip fractures are related to osteoporosis, treating accelerated bone loss can be an important strategy to prevent hip fractures. Thiazides have been associated with reduced age-related bone loss by decreasing urinary calcium excretion.To examine the association between dose and duration of thiazide diuretic use and the risk for hip fracture and to study the consequences of discontinuing use.Prospective population-based cohort study.The Rotterdam Study.7891 individuals 55 years of age and older.Hip fractures were reported by the general practitioners and verified by trained research assistants. Details of all dispensed drugs were available on a day-to-day basis. Exposure to thiazides was divided into 7 mutually exclusive categories: never use, current use for 1 to 42 days, current use for 43 to 365 days, current use for more than 365 days, discontinuation of use since 1 to 60 days, discontinuation of use since 61 to 120 days, and discontinuation of use since more than 120 days.281 hip fractures occurred. Relative to nonuse, current use of thiazides for more than 365 days was statistically significantly associated with a lower risk for hip fracture (hazard ratio, 0.46 [95% CI, 0.21 to 0.96]). There was no clear dose dependency. This lower risk disappeared approximately 4 months after thiazide use was discontinued.Thiazide diuretics protect against hip fracture, but this protective effect disappears within 4 months after use is discontinued.
Overcoming Immunization Barriers
Authors: Jane S. Durch
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Negative-pressure plastic isolator for patients with dangerous infections.
Authors: P C Trexler, R T Emond, B Evans
Journal: BMJ (1977)

A negative-pressure plastic isolator is effective for dealing with patients suffering from dangerous infections. So far it has been used to treat seven patients suspected of having infections due to Lassa, Marburg, or Ebola viruses. One patient spent 32 days in the isolator. The isolator was proved comfortable and acceptable to patients, and it gives the nursing and medical attendants a high degree of protection. All routine nursing and medical procedures can be carried out with minimal interference by the physical barrier, though it is not practicable to undertake artificial respiration or haemodialysis.
Survival in young patients with intermediate‐/high‐risk myelofibrosis: Estimates derived from databases for non transplant patients
Authors: Sergio Siragusa, Francesco Passamonti, Francisco Cervantes, Ayalew Tefferi
Journal: American Journal of Hematology (2008)

Abstract Recent studies have suggested that allogenic stem cell transplantation (allo‐SCT) might be a better treatment option, compared to drug therapy, for young patients with high‐/intermediate‐risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo‐SCT is associated with a substantial risk of procedure‐related mortality and morbidity. In a retrospective analysis of nontransplant PMF patients, who were both young (age &lt;60 years) and with high‐/intermediate‐risk disease, 1‐ and 3‐year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these data did not appear to be inferior to those published in the context of either myeloablative or reduced‐intensity conditioning allo‐SCT. These observations underscore the need for controlled studies to accurately assess the value of allo‐SCT in PMF. AM. J. Hematol. 2009. © 2008 Wiley‐Liss, Inc.
Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporin therapy
Authors: M.J. KORSTANJE, H.J.G. BILO, T.J. STOOF
Journal: British Journal of Dermatology (1992)

Eight patients with psoriasis received low-dose cyclosporin (CyA) treatment for an average period of 12 months (range 4-16 months). There was great variability in minimal effective CyA dose. In 50% of the patients long-term treatment was limited by dose reductions necessitated by side-effects. A considerable impairment of renal function during CyA therapy was found. Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured with 125I-iothalamate and 131I-hippuran, respectively. Both at the end of the active treatment period (GFR-CyA and ERPF-CyA), and 4 months after withdrawal of CyA (GFR-4mo and ERPF-4mo), there was sustained renal impairment: GFR-BL = 97 (64-117), GFR-CyA reduction 17.8% (2.2-31.9%) [P < 0.02], GFR-4mo reduction = 9.8% (5.5-21.5%) ml/min/1.73 m2 (P < 0.05 vs. BL); ERPF-BL = 401 (232-607), ERPF-CyA reduction = 10.1% (7.4-27.3%) [P < 0.05], ERPF-4mo reduction = 13.5% (3.0-32.9%) ml/min/1.73 m2 (P < 0.02). Further studies of the effects on renal function during, and after, long-term therapy of psoriasis with low-dose CyA are warranted.
Abstract A41: Effect of dietary vitamin D3 and calcium on the growth of androgeninsensitive human prostate tumor in a murine model
Authors: Rahul Ray, Mara Banks, Hilal Abuzahra, Kelly S. Persons, Vikram J. Eddy, James R. Lambert, Michael F. Holick
Journal: Cancer Research (2012)

Abstract Vitamin D deficiency has been associated with increased risk of prostate cancer in epidemiologic and prospective studies. An association has also been made between high dietary calcium and increased prostate cancer risk. Previous studies have demonstrated that normal prostate cells and some prostate cancer cells have the ability to convert 25(OH)D to 1α,25(OH)2D. This ability along with epidemiological evidence correlating an inverse relationship between serum 25(OH)D levels and prostate cancer risk suggests that vitamin D may be important for prostate cancer prevention. The effect of dietary vitamin D and calcium on the growth of human androgen-insensitive prostate tumor in an athymic mouse model was evaluated. Three factors were considered in evaluating the role of dietary calcium and vitamin D on prostate tumor in our mice model: tumor-growth, elevation of serum calcium and overall growth of the animals (body weight). Immunohistochemical staining and Real Time PCR analysis were performed on tumors to elucidate the molecular mechanism(s) involved in vitamin D regulation of prostate cancer. Tumor-growth was highest in normal calcium, vitamin D deficient diet group (381±59 mm3) while growth in normal calcium, vitamin D sufficient (179±36 mm3), high calcium, vitamin D sufficient (199±25 mm3) and deficient (204±43 mm3) diets were not significantly different from one another. The normal calcium, vitamin D deficient diet had mice that were normo-calcemic compared to the other diet groups though there was no significant difference between groups for the weights of the animals. Proliferative (Ki67) and apoptotic (Caspase 3) staining revealed no significant difference between vitamin D sufficient and deficient diet groups. Additional staining for p21 did not show any difference among the diet groups. Gene analysis for p21, p27 and p53 did not demonstrate altered transcriptional activity in vitamin D sufficient groups. Bax and bcl-2 mRNA expression were both increased in the high calcium, vitamin D deficient diet group. The difference in tumor growth between the normal calcium, vitamin D deficient diet and the other diets suggest an important role of dietary vitamin D as a preventive agent in androgen-insensitive prostate cancer. More in vivo studies are needed to understand the molecular mechanism(s) behind vitamin D's antitumorigenic effects. Citation Format: Rahul Ray, Mara Banks, Hilal Abuzahra, Kelly S. Persons, Vikram J. Eddy, James R. Lambert, Michael F. Holick. Effect of dietary vitamin D3 and calcium on the growth of androgeninsensitive human prostate tumor in a murine model [abstract]. In: Proceedings of the AACR Special Conference on Advances in Prostate Cancer Research; 2012 Feb 6-9; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(4 Suppl):Abstract nr A41.
The Wrong Patient
Authors: Linda Fermoyle Rice
Journal: Annals of Internal Medicine (2003)

Letters18 March 2003The Wrong PatientLinda Fermoyle Rice, JDLinda Fermoyle Rice, JDWoodland Hills, CA 91367 (Rice)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-138-6-200303180-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The journal's decision to highlight medical mishaps, as in the article by Chassin and Becher (1), is courageous and probably long overdue. The adversarial role between the medical and legal professions works a disservice to both professions and to the people we serve.Doctors are often reluctant to engage in candid discussions with patients, especially after a problem develops. The patient becomes frustrated. He has been injured and cannot get the information he needs to understand why or how this occurred. The physician's reticence is interpreted as indifference and as a breach of trust. Even if professional ...References1. Chassin MR, Becher EC. The wrong patient. Ann Intern Med. 2002;136:826-33. [PMID: 12044131] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Woodland Hills, CA 91367 (Rice) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Wrong Patient Mark R. Chassin and Elise C. Becher The Wrong Patient James G. Gallagher The Wrong Patient Robert M. Wachter , Kaveh G. Shojania , Sanjay Saint , Amy J. Markowitz , and Mark Smith The Wrong Patient Stephen Sandroni Metrics 18 March 2003Volume 138, Issue 6Page: 518KeywordsHealth carePatients ePublished: 18 March 2003 Issue Published: 18 March 2003 CopyrightCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
FIVE-YEAR CLINICAL OUTCOMES OF SIROLIMUS-ELUTING VERSUS PACLITAXEL-ELUTING STENTS IN HIGH RISK PATIENT SUBSETS: A POOLED ANALYSIS OF 3 RANDOMIZED TRIALS
Authors: Katrin A. Birkmeier, Adnan Kastrati, Robert A. Byrne, Klaus Tiroch, Heidrun Holle, Stefanie Schulz, Sebastian Kufner, Steffen Massberg, Karl-Ludwig Laugwitz, Albert Schö;mig, Julinda Mehilli, Deutsches Herzzentrum
Journal: Journal of the American College of Cardiology (2010)
Molecular Pathways: Protein Methyltransferases in Cancer
Authors: Robert A. Copeland
Journal: Clinical Cancer Research (2013)

Abstract The protein methyltransferases (PMT) constitute a large and important class of enzymes that catalyze site-specific methylation of lysine or arginine residues on histones and other proteins. Site-specific histone methylation is a critical component of chromatin regulation of gene transcription—a pathway that is often genetically altered in human cancers. Oncogenic alterations (e.g., mutations, chromosomal translocations, and others) of PMTs, or of associated proteins, have been found to confer unique dependencies of cancer cells on the activity of specific PMTs. Examples of potent, selective small-molecule inhibitors of specific PMTs are reviewed that have been shown to kill cancers cells bearing such oncogenic alterations, while having minimal effect on proliferation of nonaltered cells. Selective inhibitors of the PMTs, DOT1L and EZH2, have entered phase I clinical studies and additional examples of selective PMT inhibitors are likely to enter the clinic soon. The current state of efforts toward clinical testing of selective PMT inhibitors as personalized cancer therapeutics is reviewed here. Clin Cancer Res; 19(23); 6344–50. ©2013 AACR.
AMA's scheme to protect JAMA's independence has drawbacks
Authors: A. Ferriman
Journal: BMJ (1999)

The American Medical Association's new scheme to protect the editorial independence of its journal (JAMA) from interference by the association's management has several weak points, according toDr George Lundberg, the journal's former editor.

Dr Lundberg, who was dismissed from his post in January when he published an article which the association's management considered to be political, outlined his misgivings last week at a meeting in London of the BMJ's editorial board.

The scheme, known as the “editorial governance plan,” was unveiled at a press conference at theend of May and involves …
A Family Study of Hysteria
Authors: Oguz Arkonag, Samuel B. Guze
Journal: New England Journal of Medicine (1963)

ONE of us (S.B.G.) has been pursuing a series of studies to clarify the diagnostic features of hysteria and to learn more about its natural history.1 2 3 We use the term hysteria to designate the syndrome described by Briquet,4 Savill5 and Purtell et al.6 The following are the major features of this disorder: it starts early in life; it occurs primarily, if not exclusively, in women; and it is characterized by recurrent symptoms in many different organ systems. The history is described dramatically and includes recurrent and varied pains, menstrual difficulties, sexual maladjustment, headaches, anxiety symptoms, conversion symptoms and repeated hospital . . .